Pharma Industry

Natco Pharma to invest $14 mn in US-based biotechnology firm eGenesis Inc

Natco Pharma on Tuesday said it is investing USD 14 million (over Rs 130 crore) in eGenesis Inc, a US-based biotechnology firm, through its two subsidiaries. As part of the transaction, Natco Pharma (Canada) Inc will invest USD 9.5 million and Natco Pharma South Africa Proprietary Ltd USD 4.5 million in eGenesis through convertible promissory notes, the Hyderabad-based company said in a regulatory filing. eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure, it added. In 2024, Natco Pharma had invested USD 8 million in eGenesis, Inc through preferred stock. The total investment made by it in eGenesis, Inc now stands at USD 22 million, the company said. The eGenesis Genome Engineering and Production (EGEN) platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via ..

Indian pharma firms have little reason to fear Trump's tariff threat

Trump's pledge to apply 100% levy on firms making off-patent medications by 2028 (rising to 200% a year later) unless they move production to US faces formidable commercial and political obstacles

India's pharma ambitions are running into a regulatory capacity constraint

Govt's decision under the ₹10,000 cr Biopharma SHAKTI programme to create a dedicated scientific review cadre within CDSCO is an important reform

Pharma sector must move from cost competitiveness to innovation: Experts

India's pharmaceutical industry needs to move beyond its traditional strength in cost-effective generic medicines and focus on innovation, advanced manufacturing, quality and global regulatory standards to realise its growth potential, industry experts said. With India targeting a pharmaceutical market of USD 130 billion by 2030, experts at a recent industry event in Hyderabad said the next phase of growth would require greater investments in research and development, digital technologies and contract research and development manufacturing. The discussions were held ahead of the 19th edition of CPHI & PMEC India 2026, scheduled to be held in November across venues in Delhi-NCR. The official launch and precursor event of CPHI & PMEC India 2026, held under the banner of the Pharma Leadership Exchange, brought together pharma leaders, CXOs, industry stalwarts, and key voices from across India's pharmaceutical and life sciences ecosystem. Sarvesh Singh, CEO, Lifesciences and ...

Indegene eyes clinical research acquisition to widen pharma services play

The company is evaluating specialised CROs, data-management and patient-recruitment businesses as it looks to expand across the pharmaceutical value chain

Thermo Fisher eyes 15-20% India customer growth on biopharma research boost

The US-based company said it is eyeing continued double-digit growth in India driven by rising demand from biopharma, semiconductor, and clean energy sectors

Regulatory hurdles eclipse tariff worries for pharma CXOs: Deloitte survey

Industry seeks AI-based submission tools and unified digital portals to accelerate approvals and compliance tracking

Fermenta Biotech expands plant-based Vitamin D3 capacity at Dahej plant

Dahej facility to begin commercial production in FY28; company targets nutraceuticals, functional foods and import substitution

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

US proposal to impose tariffs on generic medicines could impact India: GTRI

The proposed steep tariffs announced by the US on generic medicines could significantly affect India's largest pharmaceutical export market, economic think tank GTRI said on Wednesday. However, it said that the impact is unlikely to be uniform. "Many Indian generic medicines sell for seven to ten times less than branded alternatives. Even after a 100 per cent tariff, many products could remain cheaper than branded medicines, meaning much of the additional cost would likely be passed on to US healthcare providers, insurers and patients rather than immediately eliminating Indian exports," it said. It added that the greatest pressure is expected to fall on higher-value generic formulations and branded generics, where manufacturing in the United States could become commercially viable. "The proposed tariffs could significantly affect India's largest pharmaceutical export market," Global Trade Research Initiative (GTRI) founder Ajay Srivastava said, adding that India should also reduce

Q1FY27 pharma preview: Domestic growth cushions US-led pressure on earnings

Hospitals and diagnostics are expected to outperform in Q1FY27, driven by capacity additions, improving utilisation and higher patient volumes despite pressure on margins

Lupin spins out 2 cancer drug programmes into US-based Kaveri Therapeutics

New company to raise capital for global clinical trials; Lupin to retain significant equity stake and provide seed funding

Fat-loss drug sales in India loses steam after early spike from generics

The slowdown marks a sharp deceleration from the initial rush that followed the expiry of semaglutide's patent in March

As India expands QR tracking, pharma industry looks to AI for quality

While expanded traceability aims to curb counterfeit medicines, industry says predictive manufacturing could help reduce NSQ drugs

CCI clears pharma firms, trade bodies in 14-year-old antitrust case

The antitrust watchdog rejected its Director General's findings, ruling there was no evidence of anti-competitive agreements involving stockist appointments or new drug launches

Aurobindo Pharma gets US FTC nod for $250 million acquisition of Lannett

Aurobindo Pharma on Monday said its arm Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. The transaction, valued at USD 250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of this month, Aurobindo Pharma said in a regulatory filing. Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances, the filing said. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network, it added. "This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position i

Indian pharma's next prescription: Specialty drugs, not just generics

Indian drugmakers are reducing reliance on US generics, turning to specialty medicines, biosimilars and emerging markets to drive sustainable growth

Biopharma entering innovation power decade, says Bernstein report

Brokerage says India should focus on specialty medicines and incremental innovation rather than copying Big Pharma's new-drug discovery model

Zaynich antibiotic: How Wockhardt created India's first FDA-approved drug | Pharma Industry

For decades, India excelled at making affordable generic medicines. But creating a brand-new drug from scratch remained a rare achievement. Now, Wockhardt has made history with Zaynich

Piramal Pharma to stay away from generic GLP-1 race amid global rush

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27